- Home
- DBD vs APLS Comparison
DBD vs APLS Comparison
Compare DBD & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- APLS
- Stock Information
- Founded
- DBD 1859
- APLS 2009
- Country
- DBD United States
- APLS United States
- Employees
- DBD N/A
- APLS N/A
- Industry
- DBD EDP Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- APLS Health Care
- Exchange
- DBD Nasdaq
- APLS Nasdaq
- Market Cap
- DBD 1.9B
- APLS 2.2B
- IPO Year
- DBD N/A
- APLS 2017
- Fundamental
- Price
- DBD $59.93
- APLS $19.91
- Analyst Decision
- DBD Strong Buy
- APLS Buy
- Analyst Count
- DBD 2
- APLS 19
- Target Price
- DBD $65.00
- APLS $37.39
- AVG Volume (30 Days)
- DBD 316.7K
- APLS 1.9M
- Earning Date
- DBD 08-06-2025
- APLS 07-31-2025
- Dividend Yield
- DBD N/A
- APLS N/A
- EPS Growth
- DBD N/A
- APLS N/A
- EPS
- DBD N/A
- APLS N/A
- Revenue
- DBD $3,696,800,000.00
- APLS $775,839,000.00
- Revenue This Year
- DBD $2.02
- APLS $1.01
- Revenue Next Year
- DBD $1.96
- APLS $22.14
- P/E Ratio
- DBD N/A
- APLS N/A
- Revenue Growth
- DBD N/A
- APLS 48.04
- 52 Week Low
- DBD $34.38
- APLS $16.10
- 52 Week High
- DBD $60.33
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- DBD 84.47
- APLS 62.09
- Support Level
- DBD $58.68
- APLS $17.35
- Resistance Level
- DBD $60.33
- APLS $19.63
- Average True Range (ATR)
- DBD 1.15
- APLS 0.81
- MACD
- DBD 0.35
- APLS 0.23
- Stochastic Oscillator
- DBD 95.49
- APLS 80.24
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.